Targeting p62 by sulforaphane promotes autolysosomal degradation of SLC7A11, inducing ferroptosis for osteosarcoma treatment
Osteosarcoma (OS) is the most prevalent malignant bone tumor in children and adolescents worldwide. Identification of novel therapeutic targets and development of targeted drugs are one of the most feasible strategies for OS treatment. Ferroptosis, a recently discovered mode of programmed cell death...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-02-01
|
| Series: | Redox Biology |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2213231724004385 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841542446394114048 |
|---|---|
| author | Qiuming Zou Xiaofeng Zhou Jianqin Lai Haixia Zhou Jinxuan Su Zhijing Zhang Xiaosong Zhuang Lili Liu Ruijie Yuan Sijia Li Siyu Yang Xinyi Qu Jiezhu Feng Yongqi Liu Zisheng Li Shiting Huang Zhi Shi Yu Yan Zhiming Zheng Wencai Ye Qi Qi |
| author_facet | Qiuming Zou Xiaofeng Zhou Jianqin Lai Haixia Zhou Jinxuan Su Zhijing Zhang Xiaosong Zhuang Lili Liu Ruijie Yuan Sijia Li Siyu Yang Xinyi Qu Jiezhu Feng Yongqi Liu Zisheng Li Shiting Huang Zhi Shi Yu Yan Zhiming Zheng Wencai Ye Qi Qi |
| author_sort | Qiuming Zou |
| collection | DOAJ |
| description | Osteosarcoma (OS) is the most prevalent malignant bone tumor in children and adolescents worldwide. Identification of novel therapeutic targets and development of targeted drugs are one of the most feasible strategies for OS treatment. Ferroptosis, a recently discovered mode of programmed cell death, has been implicated as a potential strategy for cancer therapy. Sulforaphane (SFN), the main bioactive compound derived from cruciferous vegetables, has shown potential anti-cancer effects with negligible toxicity. However, the role of ferroptosis in the effect of SFN on OS remains unknown. In the present study, we found that SFN acted as a potent ferroptosis inducer in OS, which was demonstrated by various inhibitors of cell death. The SFN-induced ferroptotic cell death was characterized by elevated ROS levels, lipid peroxidation, and GSH depletion, which was dependent on decreased levels of SLC7A11. Mechanically, SFN directly targeted p62 protein and enhanced p62/SLC7A11 protein-protein interaction, thereby promoting the lysosomal degradation of SLC7A11 and triggering ferroptosis. Notably, both subcutaneous and intratibial OS models in nude mice confirmed the ferroptosis associated anti-cancer efficacy of SFN in vivo. Hence, our findings demonstrate that SFN exerts its anti-cancer effects through inducing SLC7A11-dependent ferroptosis in OS, providing compelling evidence for the application of SFN in OS treatment. |
| format | Article |
| id | doaj-art-4d9e5792e8654c15997768af92f08665 |
| institution | Kabale University |
| issn | 2213-2317 |
| language | English |
| publishDate | 2025-02-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Redox Biology |
| spelling | doaj-art-4d9e5792e8654c15997768af92f086652025-01-14T04:12:09ZengElsevierRedox Biology2213-23172025-02-0179103460Targeting p62 by sulforaphane promotes autolysosomal degradation of SLC7A11, inducing ferroptosis for osteosarcoma treatmentQiuming Zou0Xiaofeng Zhou1Jianqin Lai2Haixia Zhou3Jinxuan Su4Zhijing Zhang5Xiaosong Zhuang6Lili Liu7Ruijie Yuan8Sijia Li9Siyu Yang10Xinyi Qu11Jiezhu Feng12Yongqi Liu13Zisheng Li14Shiting Huang15Zhi Shi16Yu Yan17Zhiming Zheng18Wencai Ye19Qi Qi20State Key Laboratory of Bioactive Molecules and Druggability Assessment, MOE Key Laboratory of Tumor Molecular Biology, Guangdong Province Key Laboratory of Pharmacodynamic Constituents of TCM and New Drugs Research, Department of Pharmacology, School of Medicine, Jinan University, Guangzhou, 510632, ChinaState Key Laboratory of Bioactive Molecules and Druggability Assessment, MOE Key Laboratory of Tumor Molecular Biology, Guangdong Province Key Laboratory of Pharmacodynamic Constituents of TCM and New Drugs Research, Department of Pharmacology, School of Medicine, Jinan University, Guangzhou, 510632, ChinaDepartment of Gastrointestinal Surgery, Guangzhou First People's Hospital, Guangzhou, 510180, ChinaState Key Laboratory of Bioactive Molecules and Druggability Assessment, MOE Key Laboratory of Tumor Molecular Biology, Guangdong Province Key Laboratory of Pharmacodynamic Constituents of TCM and New Drugs Research, Department of Pharmacology, School of Medicine, Jinan University, Guangzhou, 510632, ChinaState Key Laboratory of Bioactive Molecules and Druggability Assessment, MOE Key Laboratory of Tumor Molecular Biology, Guangdong Province Key Laboratory of Pharmacodynamic Constituents of TCM and New Drugs Research, Department of Pharmacology, School of Medicine, Jinan University, Guangzhou, 510632, ChinaState Key Laboratory of Bioactive Molecules and Druggability Assessment, MOE Key Laboratory of Tumor Molecular Biology, Guangdong Province Key Laboratory of Pharmacodynamic Constituents of TCM and New Drugs Research, Department of Pharmacology, School of Medicine, Jinan University, Guangzhou, 510632, ChinaState Key Laboratory of Bioactive Molecules and Druggability Assessment, MOE Key Laboratory of Tumor Molecular Biology, Guangdong Province Key Laboratory of Pharmacodynamic Constituents of TCM and New Drugs Research, Department of Pharmacology, School of Medicine, Jinan University, Guangzhou, 510632, ChinaState Key Laboratory of Bioactive Molecules and Druggability Assessment, Center for Bioactive Natural Molecules and Innovative Drugs Research, Guangdong Basic Research Center of Excellence for Natural Bioactive Molecules and Discovery of Innovative Drugs, Guangdong Province Key Laboratory of Pharmacodynamic Constituents of TCM and New Drugs Research, College of Pharmacy, Jinan University, Guangzhou, 510632, ChinaState Key Laboratory of Bioactive Molecules and Druggability Assessment, MOE Key Laboratory of Tumor Molecular Biology, Guangdong Province Key Laboratory of Pharmacodynamic Constituents of TCM and New Drugs Research, Department of Pharmacology, School of Medicine, Jinan University, Guangzhou, 510632, ChinaState Key Laboratory of Bioactive Molecules and Druggability Assessment, MOE Key Laboratory of Tumor Molecular Biology, Guangdong Province Key Laboratory of Pharmacodynamic Constituents of TCM and New Drugs Research, Department of Pharmacology, School of Medicine, Jinan University, Guangzhou, 510632, ChinaState Key Laboratory of Bioactive Molecules and Druggability Assessment, MOE Key Laboratory of Tumor Molecular Biology, Guangdong Province Key Laboratory of Pharmacodynamic Constituents of TCM and New Drugs Research, Department of Pharmacology, School of Medicine, Jinan University, Guangzhou, 510632, ChinaState Key Laboratory of Bioactive Molecules and Druggability Assessment, MOE Key Laboratory of Tumor Molecular Biology, Guangdong Province Key Laboratory of Pharmacodynamic Constituents of TCM and New Drugs Research, Department of Pharmacology, School of Medicine, Jinan University, Guangzhou, 510632, ChinaSchool of Medicine, South China University of Technology, Guangzhou, 510006, ChinaState Key Laboratory of Bioactive Molecules and Druggability Assessment, MOE Key Laboratory of Tumor Molecular Biology, Guangdong Province Key Laboratory of Pharmacodynamic Constituents of TCM and New Drugs Research, Department of Pharmacology, School of Medicine, Jinan University, Guangzhou, 510632, ChinaState Key Laboratory of Bioactive Molecules and Druggability Assessment, MOE Key Laboratory of Tumor Molecular Biology, Guangdong Province Key Laboratory of Pharmacodynamic Constituents of TCM and New Drugs Research, Department of Pharmacology, School of Medicine, Jinan University, Guangzhou, 510632, ChinaState Key Laboratory of Bioactive Molecules and Druggability Assessment, MOE Key Laboratory of Tumor Molecular Biology, Guangdong Province Key Laboratory of Pharmacodynamic Constituents of TCM and New Drugs Research, Department of Pharmacology, School of Medicine, Jinan University, Guangzhou, 510632, ChinaDepartment of Cell Biology & Institute of Biomedicine, Guangdong Provincial Biotechnology & Engineering Technology Research Center, Guangdong Provincial Key Laboratory of Bioengineering Medicine, Genomic Medicine Engineering Research Center of Ministry of Education, MOE Key Laboratory of Tumor Molecular Biology, National Engineering Research Center of Genetic Medicine, State Key Laboratory of Bioactive Molecules and Druggability Assessment, College of Life Science and Technology, Jinan University, Guangzhou, 510632, ChinaFunctional Experimental Teaching Center, School of Medicine, Jinan University, Guangzhou, 510632, China; Corresponding author.Department of Neurosurgery, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, 250021, China; Corresponding authors.State Key Laboratory of Bioactive Molecules and Druggability Assessment, Center for Bioactive Natural Molecules and Innovative Drugs Research, Guangdong Basic Research Center of Excellence for Natural Bioactive Molecules and Discovery of Innovative Drugs, Guangdong Province Key Laboratory of Pharmacodynamic Constituents of TCM and New Drugs Research, College of Pharmacy, Jinan University, Guangzhou, 510632, China; Corresponding author.State Key Laboratory of Bioactive Molecules and Druggability Assessment, MOE Key Laboratory of Tumor Molecular Biology, Guangdong Province Key Laboratory of Pharmacodynamic Constituents of TCM and New Drugs Research, Department of Pharmacology, School of Medicine, Jinan University, Guangzhou, 510632, China; Corresponding authors.Osteosarcoma (OS) is the most prevalent malignant bone tumor in children and adolescents worldwide. Identification of novel therapeutic targets and development of targeted drugs are one of the most feasible strategies for OS treatment. Ferroptosis, a recently discovered mode of programmed cell death, has been implicated as a potential strategy for cancer therapy. Sulforaphane (SFN), the main bioactive compound derived from cruciferous vegetables, has shown potential anti-cancer effects with negligible toxicity. However, the role of ferroptosis in the effect of SFN on OS remains unknown. In the present study, we found that SFN acted as a potent ferroptosis inducer in OS, which was demonstrated by various inhibitors of cell death. The SFN-induced ferroptotic cell death was characterized by elevated ROS levels, lipid peroxidation, and GSH depletion, which was dependent on decreased levels of SLC7A11. Mechanically, SFN directly targeted p62 protein and enhanced p62/SLC7A11 protein-protein interaction, thereby promoting the lysosomal degradation of SLC7A11 and triggering ferroptosis. Notably, both subcutaneous and intratibial OS models in nude mice confirmed the ferroptosis associated anti-cancer efficacy of SFN in vivo. Hence, our findings demonstrate that SFN exerts its anti-cancer effects through inducing SLC7A11-dependent ferroptosis in OS, providing compelling evidence for the application of SFN in OS treatment.http://www.sciencedirect.com/science/article/pii/S2213231724004385FerroptosisSulforaphanep62SLC7A11Osteosarcoma |
| spellingShingle | Qiuming Zou Xiaofeng Zhou Jianqin Lai Haixia Zhou Jinxuan Su Zhijing Zhang Xiaosong Zhuang Lili Liu Ruijie Yuan Sijia Li Siyu Yang Xinyi Qu Jiezhu Feng Yongqi Liu Zisheng Li Shiting Huang Zhi Shi Yu Yan Zhiming Zheng Wencai Ye Qi Qi Targeting p62 by sulforaphane promotes autolysosomal degradation of SLC7A11, inducing ferroptosis for osteosarcoma treatment Redox Biology Ferroptosis Sulforaphane p62 SLC7A11 Osteosarcoma |
| title | Targeting p62 by sulforaphane promotes autolysosomal degradation of SLC7A11, inducing ferroptosis for osteosarcoma treatment |
| title_full | Targeting p62 by sulforaphane promotes autolysosomal degradation of SLC7A11, inducing ferroptosis for osteosarcoma treatment |
| title_fullStr | Targeting p62 by sulforaphane promotes autolysosomal degradation of SLC7A11, inducing ferroptosis for osteosarcoma treatment |
| title_full_unstemmed | Targeting p62 by sulforaphane promotes autolysosomal degradation of SLC7A11, inducing ferroptosis for osteosarcoma treatment |
| title_short | Targeting p62 by sulforaphane promotes autolysosomal degradation of SLC7A11, inducing ferroptosis for osteosarcoma treatment |
| title_sort | targeting p62 by sulforaphane promotes autolysosomal degradation of slc7a11 inducing ferroptosis for osteosarcoma treatment |
| topic | Ferroptosis Sulforaphane p62 SLC7A11 Osteosarcoma |
| url | http://www.sciencedirect.com/science/article/pii/S2213231724004385 |
| work_keys_str_mv | AT qiumingzou targetingp62bysulforaphanepromotesautolysosomaldegradationofslc7a11inducingferroptosisforosteosarcomatreatment AT xiaofengzhou targetingp62bysulforaphanepromotesautolysosomaldegradationofslc7a11inducingferroptosisforosteosarcomatreatment AT jianqinlai targetingp62bysulforaphanepromotesautolysosomaldegradationofslc7a11inducingferroptosisforosteosarcomatreatment AT haixiazhou targetingp62bysulforaphanepromotesautolysosomaldegradationofslc7a11inducingferroptosisforosteosarcomatreatment AT jinxuansu targetingp62bysulforaphanepromotesautolysosomaldegradationofslc7a11inducingferroptosisforosteosarcomatreatment AT zhijingzhang targetingp62bysulforaphanepromotesautolysosomaldegradationofslc7a11inducingferroptosisforosteosarcomatreatment AT xiaosongzhuang targetingp62bysulforaphanepromotesautolysosomaldegradationofslc7a11inducingferroptosisforosteosarcomatreatment AT lililiu targetingp62bysulforaphanepromotesautolysosomaldegradationofslc7a11inducingferroptosisforosteosarcomatreatment AT ruijieyuan targetingp62bysulforaphanepromotesautolysosomaldegradationofslc7a11inducingferroptosisforosteosarcomatreatment AT sijiali targetingp62bysulforaphanepromotesautolysosomaldegradationofslc7a11inducingferroptosisforosteosarcomatreatment AT siyuyang targetingp62bysulforaphanepromotesautolysosomaldegradationofslc7a11inducingferroptosisforosteosarcomatreatment AT xinyiqu targetingp62bysulforaphanepromotesautolysosomaldegradationofslc7a11inducingferroptosisforosteosarcomatreatment AT jiezhufeng targetingp62bysulforaphanepromotesautolysosomaldegradationofslc7a11inducingferroptosisforosteosarcomatreatment AT yongqiliu targetingp62bysulforaphanepromotesautolysosomaldegradationofslc7a11inducingferroptosisforosteosarcomatreatment AT zishengli targetingp62bysulforaphanepromotesautolysosomaldegradationofslc7a11inducingferroptosisforosteosarcomatreatment AT shitinghuang targetingp62bysulforaphanepromotesautolysosomaldegradationofslc7a11inducingferroptosisforosteosarcomatreatment AT zhishi targetingp62bysulforaphanepromotesautolysosomaldegradationofslc7a11inducingferroptosisforosteosarcomatreatment AT yuyan targetingp62bysulforaphanepromotesautolysosomaldegradationofslc7a11inducingferroptosisforosteosarcomatreatment AT zhimingzheng targetingp62bysulforaphanepromotesautolysosomaldegradationofslc7a11inducingferroptosisforosteosarcomatreatment AT wencaiye targetingp62bysulforaphanepromotesautolysosomaldegradationofslc7a11inducingferroptosisforosteosarcomatreatment AT qiqi targetingp62bysulforaphanepromotesautolysosomaldegradationofslc7a11inducingferroptosisforosteosarcomatreatment |